title: Intraperitoneal taxanes.
abstract: The taxanes appear to be promising agents for intraperitoneal use. Paclitaxel is currently undergoing Phase III investigation for the treatment of ovarian cancer. Docetaxel requires further Phase II study, but its impressive activity with systemic administration may be optimized with intraperitoneal administration for the treatment of peritoneal surface malignancy.
authors.affiliation: Washington Cancer Institute, Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA.
authors.forename: Faheez
authors.initials: F
authors.lastname: Mohamed
authors.forename: Paul H
authors.initials: PH
authors.lastname: Sugarbaker
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001682:Biological Availability; D017024:Chemotherapy, Adjuvant; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D020714:Maximum Tolerated Dose; D017239:Paclitaxel / Q000493:pharmacokinetics / Q000627:therapeutic use; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D043823:Taxoids / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel